Original Article
Brief Report
PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma
N Engl J Med 2008; 359:2685-2692December 18, 2008
- Abstract
Prolyl hydroxylase domain (PHD) proteins play a major role in regulating the hypoxia-inducible factor (HIF) that induces expression of genes involved in angiogenesis, erythropoiesis, and cell metabolism, proliferation, and survival. Germ-line mutations in the prolyl hydroxylase domain 2 gene (PHD2) have been reported in patients with familial erythrocytosis but not in association with tumors. We describe a patient with erythrocytosis and recurrent paraganglioma who carries a newly discovered PHD2 mutation. This mutation affects PHD2 function and stabilizes HIF-α proteins. In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene.
Media in This Article
Figure 1
PHD2 Genotypes of the Patient and His Family, and Histopathological Features of the Tumor.Figure 2
The PHD2 Mutation and Results of Loss-of-Heterozygosity Analysis of the Tumor.Article Activity
- Article
Accurate regulation of oxygen homeostasis is essential for survival. HIF, a transcription factor that activates hypoxia-inducible genes, is conserved during evolution from worms to vertebrates. It plays a central role in oxygen homeostasis during embryonic development and postnatal life but is also involved in pathologic processes such as erythrocytosis, tumor development, angiogenesis, and metastases.1
HIF is an alpha/beta heterodimer consisting of a tightly regulated alpha subunit (1α, 2α, or 3α) and a constitutively expressed beta subunit. Under normoxic conditions, HIF-α subunits are hydroxylated by dioxygenases that use oxygen as a cosubstrate.2,3 The PHD proteins (also called EGLN proteins) are dioxygenases that hydroxylate key proline residues of HIF-α, allowing for the attachment of HIF-α to the von Hippel–Lindau (VHL) tumor-suppressor protein, part of a complex that leads to the ubiquitination and degradation of HIF-α in the proteasome. In mammalian cells, there is a family of PHD proteins (PHD1, PHD2, and PHD3), among which PHD2 (also called EGLN1) seems to be the critical oxygen sensor that tags HIF-1α for destruction.2,4 In addition, factor-inhibiting HIF hydroxylates the asparagine residue in the C-terminal domain of HIF, which blocks the attachment of HIF to an essential transcriptional coactivator.5
Germ-line mutations in genes involved in the HIF pathway have been described in association with syndromes that predispose patients to either tumors or familial polycythemia. The most frequent alterations affect the VHL tumor-suppressor gene; heterozygous germ-line mutations of VHL cause VHL disease.6 This autosomal dominant condition predisposes patients to multiple vascularized tumors, including hemangioblastomas of the central nervous system and retina, clear-cell renal-cell carcinomas, pheochromocytomas, endocrine pancreatic tumors, and endolymphatic sac tumors. In contrast, a homozygous 598C→T (R200W) germ-line mutation of VHL causes Chuvash congenital polycythemia, an autosomal recessive disease reported first in residents of the Chuvash Autonomous Republic of the Russian Federation.7 Homozygous carriers of the R200W mutation have erythrocytosis, with increased erythropoietin production. Remarkably, carriers of the R200W mutation are not unduly susceptible to cancer. Heterozygous germ-line mutations in the PHD2 gene and the gene for HIF-2α (HIF2A) have been found in patients with familial erythrocytosis due to an elevated erythropoietin level, but tumors have not been reported.8-11
Germ-line mutations in genes encoding two mitochondrial enzymes operating in the Krebs cycle, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, SDHC, and SDHD), have been implicated in the development of the hereditary leiomyomatosis and renal-cell cancer syndrome and the hereditary paraganglioma–pheochromocytoma syndrome.12 In tumors deficient in FH and SDH, accumulation of the substrates (fumarate and succinate) inhibits PHD function and in this way causes overexpression of HIF.
We investigated the main genes of the HIF pathway in a patient with congenital erythrocytosis and recurrent abdominal paraganglioma.
Case Report
The patient was referred to us in 1988, when he was 30 years old and had a hematocrit value within the upper end of the normal range (Table 1Table 1
Diagnostic Tests for Erythrocytosis in the Patient at the Time of Diagnosis (1988).). Clinical and laboratory workups confirmed the diagnosis of erythrocytosis, but both routine and specialized tests failed to identify a specific cause. The erythropoietin-dependent in vitro growth of erythroid colonies ruled out the diagnosis of polycythemia vera. Phlebotomy was initiated, to maintain the hematocrit value below 45%. In addition, mild hypertension was treated with atenolol. Because the mean corpuscular volume and ferritin level remained normal on follow-up, despite the phlebotomy regimen, the patient was evaluated for, and was found to be homozygous for, the C282Y hot-spot mutation in the hemochromatosis gene HFE, which has no causal relationship to polycythemia.13 All members of the proband's family were tested, and his brother was also found to be homozygous for the C282Y mutation (and is now undergoing treatment for hemochromatosis). Neither erythrocytosis nor tumor was found in any family member other than the proband (Figure 1AFigure 1 PHD2 Genotypes of the Patient and His Family, and Histopathological Features of the Tumor.).Results of abdominal ultrasonography, repeated annually, remained normal until 2001, when the patient was 43 years old. A para-aortic mass was discovered on computed tomography (CT) and confirmed on magnetic resonance imaging. A solid, encapsulated, red-brown tumor, 3.5 by 3.5 cm, was resected, and the sections revealed two additional small nodules, 13 mm and 8 mm in diameter. On microscopical analysis, the tumor had typical features of a paraganglioma (Figure 1B).
Subsequently, the blood pressure returned to normal, atenolol was discontinued, and the hematocrit value became stabilized within the normal range without further phlebotomy. In 2003, however, urinary excretion of metanephrines was in the upper end of the normal range, and the hematocrit value rose, raising suspicion of recurrence of the tumor, which was substantiated by 131I-metaiodobenzylguanidine scintigraphy scanning in 2004.
During a second operation, the tumor, which was histologically similar to the previous one, was completely resected. The serum erythropoietin level (normal range, 5 to 25 mU per milliliter) was 48 mU per milliliter before the resection and 32 mU per milliliter 8 days after the resection. A relation between the erythrocytosis and erythropoietin production by the tumor was ruled out, however, since erythropoietin messenger RNA was not found on gene-expression assays (Taqman assay, with human hepatocellular carcinoma cells [Hep3B cells] and an erythropoietin-producing tumor associated with secondary polycythemia as controls) (data not shown). From 2004 through the time of publication of this article, the patient's clinical status has remained unchanged, with a slight elevation of hematocrit and blood pressure, both requiring treatment with phlebotomy and antihypertensive drugs. Repeated CT and 131I-metaiodobenzylguanidine scanning have not detected tumor recurrence, although urinary excretion of metanephrines has remained at twice the upper limit of the normal range during this period. The possibilities of VHL disease or the hereditary paraganglioma–pheochromocytoma syndrome were ruled out through routine genetic testing: no germ-line mutation was identified in the VHL, SDHB, SDHC, or SDHD genes.
Methods
DNA Sequencing and Loss-of-Heterozygosity Analysis
After receiving approval from our local ethics committee and obtaining written informed consent from the proband and all family members, blood samples were collected for genetic analysis. Genomic DNA was extracted from peripheral blood and paraganglioma and purified on a spin column (Qiagen). Screening for mutations in the PHD2 gene was performed by means of direct sequencing (involving a BigDye Terminator v3.1 Kit and an ABI 3730 Genetic Analyzer, both from Applied Biosystems). Sequence data were aligned using 4Peaks software (http://mekentosj.com/4peaks). Sequences of all primers used in this study are given in the Supplementary Appendix, available with the full text of this article at www.nejm.org. DNA samples from normal persons were screened for the c.1121A→G mutation (with 280 alleles tested). In silico prediction of the deleterious effect of the mutant was performed through the PolyPhen Web site (http://genetics.bwh.harvard.edu/pph) and the Panther Web site (www.pantherdb.org).
For loss-of-heterozygosity analysis, six microsatellite markers flanking the PHD2 gene (located at 1q42.1) were analyzed: D1S2877, D1S2833, D1S251, D1S2709, D1S2785, and D1S2836 (ABI PRISM Linkage Mapping Set, Applied Biosystems). Amplification was performed with the use of the Multiplex PCR Master Mix (Qiagen), according to the manufacturer's instructions. Amplified fragments were run on the genetic analyzer (ABI 3730). Data were analyzed with the use of GeneMapper software (Applied Biosystems).
Functional Analysis
The H374R PHD2 mutation was inserted into a pcDNA3-HA-PHD2 vector by means of site-directed mutagenesis (Promega). Luciferase assays were performed on human embryonic kidney 293T cells cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal-calf serum seeded in 12-well plates (2×105 cells per well) 24 hours before transfection. The transfection reagent Lipofectamine 2000 (Invitrogen) was used for transient transfections. The pcDNA3-HA-HIF-2α or HIF-1α vector (100 ng), pGL3 erythropoietin-promoter luciferase vector (200 ng), and pRenilla vector (20 ng) were cotransfected with a PHD2 (wild type, or H374R mutant) expression vector (5 to 125 ng). Luciferase activity was measured 24 hours after transfection with the use of a Dual-Luciferase Reporter Assay System (Promega). For immunoblotting, 15-μl aliquots of the lysates used in luciferase assays were run, and anti-HA (F7) antibody (Tebu) was used.
Results
Sequencing and Loss-of-Heterozygosity Analysis
We sequenced germ-line DNA obtained from the patient for genes that could be implicated in congenital polycythemia associated with a high serum erythropoietin level: PHD1, PHD2, PHD3, and HIF2A. We identified a unique c.1121A→G (p.H374R) heterozygous variation in the PHD2 gene (Figure 2AFigure 2
The PHD2 Mutation and Results of Loss-of-Heterozygosity Analysis of the Tumor.). The absence of this variant in a control population (in which 280 alleles were tested) ruled out a rare polymorphism. None of the three first-degree relatives of the patient were carriers of the PHD2 mutation. DNA of the patient's tumor was sequenced for the PHD2 gene, and the mutant allele was detected (Figure 2A). Interestingly, the chromatogram at position 1121 revealed predominantly the mutant allele, indicating a loss-of-heterozygosity of PHD2; the residual signal for the wild-type allele could be accounted for through contamination by normal tissue. Loss of heterozygosity was confirmed through microsatellite analysis of the PHD2 region, which showed monozygosity for all the markers tested (Figure 2B).Functional Studies
Consequences of the amino acid change were analyzed by computer programs, and the PolyPhen and Panther Web sites predicted that the changes observed would have a negative effect on protein function. H374 is a highly conserved residue, present in various life forms (from worms to flies to humans) and even prokaryotic pathogens (Figure 3AFigure 3
Description and Function of the p.H374R PHD2 Mutant.). Prolyl hydroxylases are dioxygenases dependent on Fe2+ and 2-oxoglutarate, and the H374 amino acid is one of the three critical residues that coordinate binding of Fe2+ ion (Figure 3B).14 Effects of the H374R mutation on PHD2 activity were evaluated by means of a reporter transcription assay. HIF-α subunits (1α or 2α) were coexpressed with a luciferase gene driven by hypoxia-responsive elements from the erythropoietin promoter gene. The addition of wild-type PHD2 caused the dose-related suppression of HIF-α–mediated induction of the reporter gene, whereas the response to the H374R PHD2 mutant was impaired. On immunoblotting used to monitor expression of the PHD2 protein, for equivalent amounts of transfected plasmid, the wild-type protein accumulated to a level that was higher than that of the mutant protein, suggesting that the mutant protein is unstable (Figure 3C). To take this effect into account, the amounts of transfected plasmid were adjusted to yield equivalent amounts of protein. With this adjustment, the impaired activity of H374R mutant was confirmed — the ratio of the activity of luciferase and that of renilla for wild-type PHD2 was, on average, 2.5 times that for mutant PHD2 (Figure 3D, which shows the results obtained for HIF-2α; the same results were observed for HIF-1α). This effect was not restricted to erythropoietin-responsive elements, since it was also obtained with the luciferase reporter gene under the control of hypoxia-responsive elements from the vascular endothelial growth factor promoter (data not shown).
Discussion
The PHD2–VHL–HIF-2α pathway plays a crucial role in erythropoiesis; a partial interruption of the pathway can cause erythrocytosis, whereas drastic alterations of the pathway are associated with the development of tumors.11,15-17 Germ-line mutations in the PHD2 gene have been reported in patients with familial erythrocytosis, but not in association with tumors.8-11 We describe here a patient with a newly discovered PHD2 mutation who first presented with isolated erythrocytosis and subsequently was found to have a recurrent paraganglioma. Tumor analysis showing loss of heterozygosity involving the wild-type PHD2 suggests that PHD2 can act as a tumor-suppressor gene. Tumor-suppressor activity of PHD2 has recently been incriminated in sporadic endometrial cancer cells and cell lines.18,19 The oncogenic processes induced by the loss of PHD2 are unknown but could involve HIF-independent pathways, since the H374 amino acid of the enzyme is part of a highly conserved catalytic core that is present even in prokaryotic pathogens that do not possess HIF. Since the H374R mutant described here perturbs the down-regulation of HIF by PHD2, and considering that paragangliomas are highly vascularized tumors, alteration of the PHD2–HIF pathway could contribute to the growth of a paraganglioma. Up to 25% of paragangliomas are hereditary and are mainly associated with germ-line mutations in the SDHB, SDHD, and VHL genes or the proto-oncogene RET.20,21 Our work suggests that PHD2 is a candidate gene involved in the development of paraganglioma and that mutation status should be explored in families with unidentified genetic alterations in the tumor.
From a clinical point of view, it is important to point out that carriers of the heterozygous germ-line PHD2 mutation who have been described in the literature are younger than our patient was at the time of diagnosis of paraganglioma (43 years of age). One exception is a 54-year-old patient with hypertension; this case could have been due to catecholamine secretion from a misdiagnosed paraganglioma.10 We recommend stringent follow-up of carriers of the germ-line PHD2 mutation, since their risk of a paraganglioma may be abnormally elevated. In addition, preclinical models with prolyl hydroxylase inhibitors to correct anemia are currently being developed. The potential oncogenic effect of this inhibition should be evaluated before the approach is considered for therapeutic use.3,22
Supported by grants from the French National Cancer Institute (Programme National d'Excellence Spécialisée Rein) and the French League against Cancer (Comités du Cher et de l'Indre).
No potential conflict of interest relevant to this article was reported.
Ms. Ladroue and Mr. Carcenac contributed equally to this article.
We thank the patient and his family for their participation and Prof. Dominique Maïza, Prof. Nicole Casadevall, Prof. Patrick Bruneval, Dr. Brigitte Bressac de Paillerets, Dr. Anne-Paule Gimenez-Roqueplo, Dr. Ahyan Ulusakarya, Johny Bombled, Caroline Chordi, and Prof. Gilbert Lenoir for their assistance.
Source Information
From Génétique Oncologique, Ecole Pratique des Hautes Etudes (EPHE) and Centre National de la Recherche Scientifique (CNRS) (FRE 2939), Institut de Cancérologie Gustave Roussy, Villejuif (C. Ladroue, R.C., S.G., J.F., S.R., B.G.); Faculté de Médecine Paris-Sud, Université Paris-Sud (C. Ladroue, R.C., S.G., S.R., B.G.), and Centre Pilote Tumeurs Rares, Institut National du Cancer and Assistance Publique–Hôpitaux de Paris, Service d'Urologie, Centre Hospitalier Universitaire de Bicêtre (S.R.) — both in Le Kremlin Bicêtre; Service d'Hématologie Clinique (M.L.), Service de Chirurgie Thoracique et Cardio-Vasculaire (C. Le Hello), and Laboratoire d'Anatomie et Cytologie Pathologiques (F.G.-S.), Centre Hospitalier Universitaire, Caen; Institute of Developmental Biology and Cancer Research, CNRS (UMR 6543) University of Nice, Nice (J.P.); and Service de Néphrologie, Hôpital Necker, Paris (S.R.) — all in France.
Address reprint requests to Dr. Richard at Génétique Oncologique EPHE, Faculté de Médecine Paris-Sud, 63 Rue Gabriel Péri, 94276 Le Kremlin-Bicêtre, France, or at stephane.richard@u-psud.fr.
- References
References
1
Semenza GL . Life with oxygen. Science 2007;318:62-64
CrossRef | Web of Science | Medline2
Berra E ,Ginouves A ,Pouyssegur J . The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 2006;7:41-45
CrossRef | Web of Science | Medline3
Kaelin WG Jr ,Ratcliffe PJ . Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402
CrossRef | Web of Science | Medline4
Ivan M ,Haberberger T ,Gervasi DC , et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002;99:13459-13464
CrossRef | Web of Science | Medline5
Lisy K ,Peet DJ . Turn me on: regulating HIF transcriptional activity. Cell Death Differ 2008;15:642-649
CrossRef | Web of Science | Medline6
Richard S ,Graff J ,Lindau J ,Resche F . Von Hippel-Lindau disease. Lancet 2004;363:1231-1234
CrossRef | Web of Science | Medline7
Ang SO ,Chen H ,Hirota K , et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-621
CrossRef | Web of Science | Medline8
Percy MJ ,Zhao Q ,Flores A , et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006;103:654-659
CrossRef | Web of Science | Medline9
Percy MJ ,Furlow PW ,Beer PA ,Lappin TR ,McMullin MF ,Lee FS . A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 2007;110:2193-2196
CrossRef | Web of Science | Medline10
Al-Sheikh M ,Moradkhani K ,Lopez M ,Wajcman H ,Prehu C . Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol Dis 2008;40:160-165
CrossRef | Web of Science | Medline11
Percy MJ ,Furlow PW ,Lucas GS , et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008;358:162-168
Full Text | Web of Science | Medline12
Eng C ,Kiuru M ,Fernandez MJ ,Aaltonen LA . A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202
CrossRef | Web of Science | Medline13
Allen KJ ,Gurrin LC ,Constantine CC , et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230
Full Text | Web of Science | Medline14
McDonough MA ,Li V ,Flashman E , et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci U S A 2006;103:9814-9819
CrossRef | Web of Science | Medline15
Minamishima YA ,Moslehi J ,Bardeesy N ,Cullen D ,Bronson RT ,Kaelin WG Jr . Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111:3236-3244
CrossRef | Web of Science | Medline16
Pouyssegur J ,Dayan F ,Mazure NM . Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-443
CrossRef | Web of Science | Medline17
Takeda K ,Cowan A ,Fong GH . Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007;116:774-781
CrossRef | Web of Science | Medline18
Lee K ,Lynd JD ,O'Reilly S ,Kiupel M ,McCormick JJ ,LaPres JJ . The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008;6:829-842
CrossRef | Web of Science | Medline19
Kato H ,Inoue T ,Asanoma K ,Nishimura C ,Matsuda T ,Wake N . Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1. Int J Cancer 2006;118:1144-1153
CrossRef | Web of Science | Medline20
Neumann HP ,Bausch B ,McWhinney SR , et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-1466
Full Text | Web of Science | Medline21
Gimenez-Roqueplo AP ,Burnichon N ,Amar L ,Favier J ,Jeunemaitre X ,Plouin PF . Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. Clin Exp Pharmacol Physiol 2008;35:376-379
CrossRef | Web of Science | Medline22
Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007;110:2140-7
- Citing Articles (39)
Citing Articles
1
M. Jafri, E. R. Maher. (2012) GENETICS IN ENDOCRINOLOGY: The genetics of phaeochromocytoma: using clinical features to guide genetic testing. European Journal of Endocrinology 166:2, 151-158
CrossRef2
Andreas Muth, Frida Abel, Svante Jansson, Ola Nilsson, Håkan Ahlman, Bo Wängberg. (2012) Prevalence of Germline Mutations in Patients with Pheochromocytoma or Abdominal Paraganglioma and Sporadic Presentation: A Population-Based Study in Western Sweden. World Journal of Surgery
CrossRef3
J. Welander, P. Soderkvist, O. Gimm. (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine Related Cancer 18:6, R253-R276
CrossRef4
Roland H. Wenger, Armin Kurtz. 2011. Erythropoietin. .
CrossRef5
Norlela Sukor. (2011) Endocrine hypertension — Current understanding and comprehensive management review. European Journal of Internal Medicine 22:5, 433-440
CrossRef6
Juan Cadiñanos, José L. Llorente, Jorge de la Rosa, José A. Villameytide, Rafael Illán, Noelia S. Durán, Eduardo Murias, Rubén Cabanillas, Eben L. Rosenthal. (2011) Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. Head & Neck 33:8, 1233-1240
CrossRef7
Giuseppe Opocher, Francesca Schiavi. (2011) Functional Consequences of Succinate Dehydrogenase Mutations. Endocrine Practice 17:0, 64-71
CrossRef8
Andrzej Roszak, Witold Kędzia, Blanka Malkowska-Walczak, Piotr Pawlik, Helena Kędzia, Michał Łuczak, Margarita Lianeri, Paweł P. Jagodzinski. (2011) Reduced expression of PHD2 prolyl hydroxylase gene in primary advanced uterine cervical carcinoma. Biomedicine & Pharmacotherapy 65:4, 298-302
CrossRef9
Bing Yan, Shi Jiao, Hai-sheng Zhang, Dan-dan Lv, Jing Xue, Li Fan, Guo-hao Wu, Jing Fang. (2011) Prolyl hydroxylase domain protein 3 targets Pax2 for destruction. Biochemical and Biophysical Research Communications 409:2, 315-320
CrossRef10
K. J. Nytko, N. Maeda, P. Schlafli, P. Spielmann, R. H. Wenger, D. P. Stiehl. (2011) Vitamin C is dispensable for oxygen sensing in vivo. Blood 117:20, 5485-5493
CrossRef11
Frank S. Lee, Melanie J. Percy. (2011) The HIF Pathway and Erythrocytosis. Annual Review of Pathology: Mechanisms of Disease 6:1, 165-192
CrossRef12
Schwartz, Robert S., , Eltzschig, Holger K., Carmeliet, Peter, . (2011) Hypoxia and Inflammation. New England Journal of Medicine 364:7, 656-665
Full Text13
Annelies Fieuw, Candy Kumps, Alexander Schramm, Filip Pattyn, Björn Menten, Francesca Antonacci, Peter Sudmant, Johannes H. Schulte, N Van Roy, Sarah Vergult, Patrick G. Buckley, A De Paepe, Rosa Noguera, Rogier Versteeg, Raymond Stallings, Angelika Eggert, Jo Vandesompele, K De Preter, Frank Speleman. (2011) Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. International Journal of Cancern/a-n/a
CrossRef14
J D van der Walt. 2011. Erythrocytosis and polycythemia. , 333-345.
CrossRef15
Yun Su, Martin Loos, Natalia Giese, Eric Metzen, Markus W. Büchler, Helmut Friess, Arno Kornberg, Peter Büchler. (2011) Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Cancern/a-n/a
CrossRef16
Giuseppe Opocher, Francesca Schiavi. (2010) Genetics of pheochromocytomas and paragangliomas. Best Practice & Research Clinical Endocrinology & Metabolism 24:6, 943-956
CrossRef17
Stephanie M.J. Fliedner, Hendrik Lehnert, Karel Pacak. (2010) Metastatic Paraganglioma. Seminars in Oncology 37:6, 627-637
CrossRef18
Daniel A. Tennant, Eyal Gottlieb. (2010) HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. Journal of Molecular Medicine 88:8, 839-849
CrossRef19
D A Chan, A J Giaccia. (2010) PHD2 in tumour angiogenesis. British Journal of Cancer 103:1, 1-5
CrossRef20
Xiping Li, Scott Sutherland, Kotaro Takeda, Guo-Hua Fong, Frank S. Lee. (2010) Integrity of the prolyl hydroxylase domain protein 2:erythropoietin pathway in aging mice. Blood Cells, Molecules, and Diseases 45:1, 9-19
CrossRef21
Vitaly Kantorovich, Kathryn S. King, Karel Pacak. (2010) SDH-related pheochromocytoma and paraganglioma. Best Practice & Research Clinical Endocrinology & Metabolism 24:3, 415-424
CrossRef22
Anthony J. Gill, Diana E. Benn, Angela Chou, Adele Clarkson, Anita Muljono, Goswin Y. Meyer-Rochow, Anne Louise Richardson, Stan B. Sidhu, Bruce G. Robinson, Roderick J. Clifton-Bligh. (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Human Pathology 41:6, 805-814
CrossRef23
Gregg L. Semenza. (2010) Oxygen homeostasis. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2:3, 336-361
CrossRef24
Terhi Jokilehto, Panu M. Jaakkola. (2010) The role of HIF prolyl hydroxylases in tumour growth. Journal of Cellular and Molecular Medicine 14:4, 758-770
CrossRef25
Lily J. Huang, Yu-Min Shen, Gamze B. Bulut. (2010) Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. British Journal of Haematology 148:6, 844-852
CrossRef26
Sarah K. Harten, Margaret Ashcroft, Patrick H. Maxwell. (2010) Prolyl Hydroxylase Domain Inhibitors: A Route to HIF Activation and Neuroprotection. Antioxidants & Redox Signaling 12:4, 459-480
CrossRef27
Simon Nagel, Nick P. Talbot, Jasmin Mecinović, Thomas G. Smith, Alastair M. Buchan, Christopher J. Schofield. (2010) Therapeutic Manipulation of the HIF Hydroxylases. Antioxidants & Redox Signaling 12:4, 481-501
CrossRef28
Jing Xue, Xuebing Li, Shi Jiao, Ye Wei, Guohao Wu, Jing Fang. (2010) Prolyl Hydroxylase-3 Is Down-regulated in Colorectal Cancer Cells and Inhibits IKKβ Independent of Hydroxylase Activity. Gastroenterology 138:2, 606-615
CrossRef29
Toshio Miyata, Charles van Ypersele de Strihou. (2010) Diabetic nephropathy: a disorder of oxygen metabolism?. Nature Reviews Nephrology 6:2, 83-95
CrossRef30
Mary Frances McMullin. (2010) HIF pathway mutations and erythrocytosis. Expert Review of Hematology 3:1, 93-101
CrossRef31
R. Neil Schimke, Debra L. Collins, Catherine A. Stolle. (2010) Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. American Journal of Medical Genetics Part An/a-n/a
CrossRef32
Susanne Schlisio. (2009) Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. Journal of Cellular and Molecular Medicine 13:10, 4104-4112
CrossRef33
D. A. Tennant, R. V. Duran, H. Boulahbel, E. Gottlieb. (2009) Metabolic transformation in cancer. Carcinogenesis 30:8, 1269-1280
CrossRef34
James H. Rosing, R. Brooke Jeffrey, Teri A. Longacre, Ralph S. Greco. (2009) Massive Extra-adrenal Retroperitoneal Paraganglioma: Pre-operative Embolization and Resection. Digestive Diseases and Sciences 54:8, 1621-1624
CrossRef35
Denise A. Chan, Tiara L.A. Kawahara, Patrick D. Sutphin, Howard Y. Chang, Jen-Tsan Chi, Amato J. Giaccia. (2009) Tumor Vasculature Is Regulated by PHD2-Mediated Angiogenesis and Bone Marrow-Derived Cell Recruitment. Cancer Cell 15:6, 527-538
CrossRef36
M M Patnaik, A Tefferi. (2009) The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 23:5, 834-844
CrossRef37
(2009) PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma. New England Journal of Medicine 360:13, 1361-1362
Full Text38
Anne-Paule Gimenez-Roqueplo. (2009) Genetics of chromaffin tumors. Expert Review of Endocrinology & Metabolism 4:2, 143-151
CrossRef39
M. F. McMullin. (2009) Idiopathic erythrocytosis: a disappearing entity. Hematology 2009:1, 629-635
CrossRef
- Letters
